Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 143580
Corporate User License Price USD 6000
Corporate User License Price INR 430740
Site License Price USD 4000
Site License Price INR 287160
Request a Quote

Report Title

Genital Herpes-Pipeline Review, H2 2016

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Genital Herpes-Pipeline Review, H2 2016


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Genital Herpes-Pipeline Review, H2 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Genital Herpes-Pipeline Review, H2 2016



Executive Summary

Genital Herpes-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Genital Herpes-Pipeline Review, H2 2016', provides an overview of the Genital Herpes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Genital Herpes

The report reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Genital Herpes therapeutics and enlists all their major and minor projects

The report assesses Genital Herpes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Genital Herpes

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Genital Herpes

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Genital Herpes Overview 10

Therapeutics Development 11

Pipeline Products for Genital Herpes-Overview 11

Pipeline Products for Genital Herpes-Comparative Analysis 12

Genital Herpes-Therapeutics under Development by Companies 13

Genital Herpes-Therapeutics under Investigation by Universities/Institutes 15

Genital Herpes-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Genital Herpes-Products under Development by Companies 18

Genital Herpes-Products under Investigation by Universities/Institutes 19

Genital Herpes-Companies Involved in Therapeutics Development 20

Admedus Ltd 20

Agenus, Inc. 21

AiCuris GmbH & Co. KG 22

Foamix Pharmaceuticals Ltd. 23

Genocea Biosciences, Inc. 24

GenVec, Inc. 25

Immune Design Corp. 26

JN-International Medical Corporation 27

Mymetics Corporation 28

NanoBio Corporation 29

NanoViricides, Inc. 30

PaxVax, Inc. 31

Profectus BioSciences, Inc. 32

Redbiotec AG 33

Sanofi Pasteur SA 34

Shulov Innovative Science Ltd. 35

Starpharma Holdings Limited 36

Tomegavax, Inc. 37

Vaccibody AS 38

Vaxart, Inc. 39

Vical Incorporated 40

Genital Herpes-Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Target 42

Assessment by Mechanism of Action 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

acyclovir-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Aspidasept-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

astodrimer-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

G-103-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

GEN-002-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

GEN-003-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

genital herpes (virus like particle) vaccine-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

genital herpes vaccine-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

genital herpes vaccine-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

genital herpes vaccine-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

genital herpes vaccine-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

genital herpes vaccine-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

GV-2207-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

herpes simplex virus [type 1, 2] vaccine-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

herpes simplex virus [type 1, 2] vaccine-Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

herpes simplex virus 2 vaccine-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

herpes simplex virus 2 vaccine-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

herpes simplex virus 2 vaccine-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

herpes simplex virus 2 vaccine-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

herpes simplex virus 2 vaccine-Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

herpes simplex virus 2 vaccine-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

HSV-529-Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

pritelivir-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Small Molecule for Genital Herpes-Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

VCLHB-01-Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

VCLHM-01-Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

ZEP-3-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Genital Herpes-Dormant Projects 90

Genital Herpes-Discontinued Products 92

Genital Herpes-Product Development Milestones 93

Featured News & Press Releases 93

Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits 93

Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016 93

Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing 94

Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging 95

Feb 03, 2016: Model helps decide drug dose for clinical testing 96

Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003 96

Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003 97

Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine 98

Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015 99

May 20, 2015: Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003 99

Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences 100

Jan 07, 2015: Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes 101

Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection 102

Jun 26, 2014: Agenus Vaccine Shows Significant Reduction in Viral Burden After HerpV Generated Immune Activation 103

Nov 07, 2013: Agenus' HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial 104

Appendix 106

Methodology 106

Coverage 106

Secondary Research 106

Primary Research 106

Expert Panel Validation 106

Contact Us 106

Disclaimer 107

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for Genital Herpes, H2 2016 11

Number of Products under Development for Genital Herpes-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Genital Herpes-Pipeline by Admedus Ltd, H2 2016 20

Genital Herpes-Pipeline by Agenus, Inc., H2 2016 21

Genital Herpes-Pipeline by AiCuris GmbH & Co. KG, H2 2016 22

Genital Herpes-Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 23

Genital Herpes-Pipeline by Genocea Biosciences, Inc., H2 2016 24

Genital Herpes-Pipeline by GenVec, Inc., H2 2016 25

Genital Herpes-Pipeline by Immune Design Corp., H2 2016 26

Genital Herpes-Pipeline by JN-International Medical Corporation, H2 2016 27

Genital Herpes-Pipeline by Mymetics Corporation, H2 2016 28

Genital Herpes-Pipeline by NanoBio Corporation, H2 2016 29

Genital Herpes-Pipeline by NanoViricides, Inc., H2 2016 30

Genital Herpes-Pipeline by PaxVax, Inc., H2 2016 31

Genital Herpes-Pipeline by Profectus BioSciences, Inc., H2 2016 32

Genital Herpes-Pipeline by Redbiotec AG, H2 2016 33

Genital Herpes-Pipeline by Sanofi Pasteur SA, H2 2016 34

Genital Herpes-Pipeline by Shulov Innovative Science Ltd., H2 2016 35

Genital Herpes-Pipeline by Starpharma Holdings Limited, H2 2016 36

Genital Herpes-Pipeline by Tomegavax, Inc., H2 2016 37

Genital Herpes-Pipeline by Vaccibody AS, H2 2016 38

Genital Herpes-Pipeline by Vaxart, Inc., H2 2016 39

Genital Herpes-Pipeline by Vical Incorporated, H2 2016 40

Assessment by Monotherapy Products, H2 2016 41

Number of Products by Stage and Target, H2 2016 43

Number of Products by Stage and Mechanism of Action, H2 2016 45

Number of Products by Stage and Route of Administration, H2 2016 47

Number of Products by Stage and Molecule Type, H2 2016 49

Genital Herpes-Dormant Projects, H2 2016 90

Genital Herpes-Dormant Projects (Contd..1), H2 2016 91

Genital Herpes-Discontinued Products, H2 2016 92

List of Figures

Number of Products under Development for Genital Herpes, H2 2016 11

Number of Products under Development for Genital Herpes-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 41

Number of Products by Targets, H2 2016 42

Number of Products by Stage and Targets, H2 2016 42

Number of Products by Mechanism of Actions, H2 2016 44

Number of Products by Stage and Mechanism of Actions, H2 2016 44

Number of Products by Routes of Administration, H2 2016 46

Number of Products by Stage and Routes of Administration, H2 2016 46

Number of Products by Molecule Types, H2 2016 48

Number of Products by Stage and Molecule Types, H2 2016 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Admedus Ltd

Agenus, Inc.

AiCuris GmbH & Co. KG

Foamix Pharmaceuticals Ltd.

Genocea Biosciences, Inc.

GenVec, Inc.

Immune Design Corp.

JN-International Medical Corporation

Mymetics Corporation

NanoBio Corporation

NanoViricides, Inc.

PaxVax, Inc.

Profectus BioSciences, Inc.

Redbiotec AG

Sanofi Pasteur SA

Shulov Innovative Science Ltd.

Starpharma Holdings Limited

Tomegavax, Inc.

Vaccibody AS

Vaxart, Inc.

Vical Incorporated

Genital Herpes Therapeutic Products under Development, Key Players in Genital Herpes Therapeutics, Genital Herpes Pipeline Overview, Genital Herpes Pipeline, Genital Herpes Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand